BIOA · NASDAQ
BioAge Labs Inc.
$6.00 +0.05 (+0.84%)
Company overview
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allow users to identify targets based on insights into molecular changes that drive aging. Its product candidate includes azelaprag, an orally available small molecule in Phase 1 clinical trials for the treatment of obesity, and it has initiated a Phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $226M
- Employees
- 61
- Headquarters
- Emeryville, CA
- Website
- bioagelabs.com
- CEO
- Kristen Fortney
- Listed
- September 26, 2024
- P/E
- -2.50
- Dividend yield
- 0.00%
Company financials
- Revenue
- $10.3M
- Gross profit
- $10.3M
- Operating income
- -$102M
- EBITDA
- -$92.4M
- Net income
- -$89.9M
- EPS
- -$2.40
- Total assets
- $398M
- Total debt
- $4M
- Gross margin
- 99.39%
- Net margin
- -871.75%
- Earnings yield
- -40.00%
No annual segmentation.
No geographic segmentation.
BIOA
1D
NASDAQ
O6.09H6.26L5.82C5.95+0.01 (+0.17%)Vol274.39K